The Worldwide Problem of Obesity - Comparison of the Effectiveness of Pharmacological Treatment with Semaglutide and Tirzepatide in Reducing Body Weight
DOI:
https://doi.org/10.12775/JEHS.2025.79.58305Keywords
Obesity treatment, Ozempic, Semaglutide, Mounjaro, Tirzepatide, Body weight loss, GLP-1 analogues, ObesityAbstract
Introduction
Obesity is a disease that has been affecting an increasing number of people in the last decade. In addition to surgical and dietary treatment, pharmacological treatment plays an important role in its treatment. Obesity is a risk factor for many diseases, including cardiovascular disease and diabetes, and increases the risk of mortality, which is why appropriate treatment is so important. Comparison of pharmacological treatment methods using two preparations from the group of GLP-1 analogues, such as semaglutide and tirzepatide, available for prescription use in European Union countries, may help select the most effective therapy tailored to the patient.
Aim of the body
The aim of the study was to summarise and compare the two preparations available for use by patients in terms of their mode of action and their impact on body weight reduction.
Methods and Materials
The following keywords were used to review the literature available in the PubMed database: "obesity", "semaglutide", "tirzepatide", "weight loss after semaglutide treatment", "weight loss after tirzepatide treatment" and "treatment of obesity". We also used literature available in other scientific journals, literature available on Google Scholar and data collected and stored by WHO.
References
1. Rueda Clausen C.F., Poddar M., Lear S.A. i wsp.: Canadian Adult Obesity Clinical Practice Guidelines: Assessment of People Living with Obesity. https://obesitycanada.ca/guide‑ lines/assessment
2. World Health Organization (WHO): Obesity and overweight.
https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 06.01.2025)
3. GBD 2019 Risk Factor Collaborators. “Global Burden of 87 Risk Factors in 204 Countries and Territories, 1990–2019: a systematic analysis for the global burden of disease study 2019”. Lancet. 2020;396:1223–1249.
4. Szymocha M, Bryła M, Maniecka-Bryła I. The obesity epidemic in 21th Century. Zdr Publ 2009, 119: 207-212. Polish
5. Szatkowska A, Bodalski J. Childhood and Adolescent Obesity: A Doctor's Guide 2003 Polish
6. Sweeting H. Measurement and Definitions of Obesity In Childhood and Adolescence a field guide forthe uninitiated. Nutritional J 2007
7. Bryl W, Hoffman K, Miczke A, Pupek-Musialik D. Obesity at a young age – epidemiology, health consequences, need for prevention. Przew Lek 2006 Polish
8. Obuchowicz A. Epidemiology of overweight and obesity – a growing health problem in the population of children and adolescents. Endocrinology, Obesity Metabolic Disorders 2005 Polish
9. Position of the Polish Society for the Treatment of Obesity, Clinical recommendations for the treatment of patients with obesity 2024 https://ptlo.org.pl/resources/data/forms/aktualnosci/258/ws_ptlo_otylosc_2024_final.pdf (accessed on 06.01.2025) Polish
10. Olszanecka-Glinianowicz M. at al: Treating overweight and obesity during and after the pandemic. Let's not wait for complications to develop - new guidelines for doctors; Nutrition, Obesity & Metabolic Surgery 2; June 2020. Polish
11. Bogdański P. et al.: Interdisciplinary position on the diagnosis and treatment of obesity. Metabolic Disorders Forum 2020, tom 11, nr 2, 47–54. Polish
12. European Medicines Agency, Wegovy - Medicine Overview Wegovy | European Medicines Agency (EMA) (acessed on 6.01.2025)
13. Alhadeff, A. L., Rupprecht, L. E., Hayes, M. R.; Endogenous Glucagon-like Peptide-1 Suppresses High-Fat Food Intake by Reducing Synaptic Excitation of Mesolimbic Dopamine Neurons; Cell Reports 2015, 12; 1-10 doi: 10.1016/j.celrep.2015.06.001 link: PubMed - Cell Reports (acessed on 6.01.2025)
14. Peyton W. Moore, Kevin Malone, Delena VanValkenburg, Lauren L. Rando, Brooke C. Williams, Hannah G. Matejowsky, Shahab Ahmadzadeh, Sahar Shekoohi, Elyse M. Cornett & Alan D. Kaye; GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications; Published 24 December 2022, Advances in Therapy Volume 40, pages 723-742, (2023)
15. R.G. Yip, M.M. Wolfe. GIP biology and fat metabolism. „Life Sci”. 66 (2), s. 91–103, 2000. PMID: 10666005
16. Yamada Y, Seino Y (2004). "Physiology of GIP--a lesson from GIP receptor knockout mice". Hormone and Metabolic Research. 36 (11–12): 771–4. doi:10.1055/s-2004-826162. PMID 15655707. S2CID 262453421
17. Wegovy prescribing information. Updated June 2021. US Food and Drug Administration https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf (2022).
18. Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP et al. Two year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. October 2022; 28(10):2083-91
19. Daniel J. Drucker; Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1; Volume 27, Issue 4, 3 April 2018, Pages 740-756 CellPress
20. "Ozempic- semaglutide injection, solution". DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021.
21.Singh G, Krauthamer M, Bjalme-Evans M (January 2022). "Wegovy (semaglutide): a new weight loss drug for chronic weight management". Journal of Investigative Medicine. 70 (1): 5–13. doi:10.1136/jim-2021-001952. PMC 8717485. PMID 34706925.
22. Phillips A, Clements JN (February 2022). "Clinical review of subcutaneous semaglutide for obesity". Journal of Clinical Pharmacy and Therapeutics. 47 (2): 184–193. doi:10.1111/jcpt.13574. PMID 34964141. S2CID 245538758.
23. Amaro A, Sugimoto D, Wharton S (January 2022). "Efficacy and safety of semaglutide for weight management: evidence from the STEP program". Postgraduate Medicine. 134 (sup1): 5–17. doi:10.1080/00325481.2022.2147326. PMID 36691309. S2CID 256192982.
24. "Drug Approval Package: Ozempic (semaglutide) Injection". US Food and Drug Administration (FDA).
25. "Semaglutide Drug Usage Statistics, United States, 2013 - 2022". ClinCalc.
26. Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al.. "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity". Diabetes, Obesity & Metabolism. 19 (9): 1242–1251. doi:10.1111/dom.12932. PMC 5573908. PMID 28266779.
27. Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. (September 2015). "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide". Journal of Medicinal Chemistry. 58 (18): 7370–80. doi:10.1021/acs.jmedchem.5b00726. PMID 26308095. S2CID 20228358.
28. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A. LY3298176, a novel dual GIPandGLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. PMID: 30473097; PMCID: PMC6308032.
29. European Medicines Agency, Mounjaro Mounjaro | European Medicines Agency (EMA) (acessed on 6.01.2025)
30. FDA Approves New Medication for Chronic Weight Management
https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management?utm_source=chatgpt.com (acessed on 6.01.2025)
31. Julio Rosenstock, Carol Wysham, Juan P Frías, Shizuka Kaneko, Clare J Lee, Laura Fernández Landó, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial; The Lancet Volume 398, Issue 10295, p143-155, July 10, 2021
32. Ania M. Jastreboff, M.D., Ph.D., Louis J. Aronne, M.D., Nadia N. Ahmad, M.D., M.P.H., Sean Wharton, M.D., Pharm.D., Lisa Connery, et al. Tirzepatide Once Weekly for the Treatment of Obesity, The New English Journal of Medicine, Published June 4, 2022 N Engl J Med 2022; 387:205-216 DOI: 10.1056/NEJMoa2206038 VOL. 387 NO. 3
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Karolina Garbino, Katarzyna Brudniak, Magdalena Czyczerska, Antoni Szuścik, Katarzyna Gadżała, Sabina Przygodzka, Maciej Mach, Maciej Rutkiewicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 15
Number of citations: 0
